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Feline immunodeficiency virus (FIV) induces a disease similar to AIDS in cats, yet in 
contrast to HIV, CD4 is not the viral receptor.   Here, we identify a primary receptor 
for FIV as CD134 (OX40), a T cell activation antigen and co-stimulatory molecule.  
CD134 expression promotes viral binding and renders cells permissive for viral entry, 
productive infection and syncytium formation. Infection is CXCR4-dependent, 
analogous to infection with X4 strains of HIV.  Thus, despite the evolutionary 
divergence of the feline and human lentiviruses, both viruses utilise receptors that 
target the virus to a subset of cells  pivotal to the acquired immune response.   
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       The primary event in the process of viral entry into a target cell is the  interaction 
between the virus and its cellular receptor and the specificity of this interaction 
determines both viral cell tropism and pathogenicity.  For the primate lentiviruses the 
viral receptor is CD4, targeting the virus to  helper T cells, resulting in their depletion 
and the eventual development of AIDS (1).  However, CD4-expression alone is 
insufficient to confer susceptibility to infection with HIV, which also depends on 
expression of co-receptors, principally the chemokine receptors CXCR4 and CCR5 
(2). The virus attaches via a high affinity interaction with CD4, resulting in a 
conformational change in the envelope glycoprotein (Env) and exposing the binding 
site for the chemokine receptor (3). This then triggers a further conformational change 
that exposes the fusion domain of the viral transmembrane protein gp41 and enables 
fusion of the viral and cellular membranes (4). 
The feline immunodeficiency virus (FIV) is unique among the non-primate 
lentiviruses in that in its natural host species, the domestic cat, it induces a disease 
similar to AIDS, characterised by a progressive depletion of CD4+ T lymphocytes (5). 
Consequently, an immunodeficiency syndrome develops characterised by wasting, 
neurological manifestations, chronic stomatitis and gingivitis and an increased 
incidence of lymphoma (6).  However, CD4 is not the primary receptor for FIV, 
suggesting that the virus may bind to an alternative molecule in order to target CD4+ 
T cells (7). Partial elucidation of the mechanism of infection with FIV was provided 
by the discovery that primary isolates and laboratory strains of virus use CXCR4 as a 
co-factor for infection (8,9). However CXCR4 expression alone was insufficient to 
confer susceptibility to infection with primary isolates of FIV, indicating the existence 
of an as yet unidentified primary receptor for the virus.  
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To identify the primary receptor for FIV, we generated a cDNA library in the 
pMX retroviral vector from an IL2-dependent CD4+ feline  T cell line (MYA-1), 
which is highly susceptible to infection with FIV (10). Following transduction of 
P3U1 murine myeloma cells with the library, cells capable of binding FIV were 
identified by “panning” with FIV-coated plates (11). Positive colonies were expanded 
and genomic DNA  prepared and the cDNA insert amplified from the retroviral vector 
by PCR.  Of three cDNAs cloned from the library, only one showed reproducible 
binding to FIV when re-expressed in P3U1 cells and was characterised as the feline 
homologue of CD134 (DDBJ accession no. AB128982). CD134 was first described as 
MRC OX-40, an antigen expressed on activated rat CD4+ T lymphocytes and a novel 
member of the TNF-NGF receptor family (12,13). The  feline CD134 cDNA identified 
here predicts a 270 amino acid protein with strong identity to human CD134 (Fig. 1A). 
To confirm that the feline CD134 protein binds FIV, we expressed the cDNA in the 
human cell line Plat-E and the murine cell line NIH-3T3. Specific FIV binding was 
detected on Plat-E and NIH 3T3 cells transduced with CD134 but not with cells 
expressing CD2 from the same vector  (Fig. 1B.).  
To assess whether CD134 acts as a functional viral receptor, the feline large 
granular lymphoma cell line MCC (these cells are refractory to infection with primary 
strains of FIV) was stably transduced with a retroviral vector bearing the CD134 
cDNA. Surface CD134 expression was detected by flow cytometry (Fig. 2A) while  a 
~45kDa species was detected by immunoblotting (Fig. 2B). CD134-expression 
rendered MCC cells permissive for infection with the five primary strains of FIV 
tested (Fig. 2C) while cells transduced with vector only remained non-permissive.  To 
quantify viral entry into the CD134-expressing cells, we prepared HIV pseudotypes 
bearing FIV Env proteins and carrying a luciferase gene. Each successful entry event 
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would trigger luciferase production in the target cells. MCC-CD134  cells were 
permissive for infection with pseudotypes bearing the Env proteins of either the GL8 
or TM2 strains of FIV (Fig. 2D.), confirming that CD134 expression overcame the 
block to viral entry into these cells.  CD134-expression also relieved the block to 
infection in the feline fibroblast line AH927 while a control vector encoding the 
FeLV-C receptor (FeLVC-R) had no effect  (Fig.S1).  
Syncytium formation occurs when Env expressed on the surface of a cell 
comes into contact with an adjacent cell expressing the viral receptor and co-receptor 
(4). Thus, transfection of cells expressing the viral receptor and co-receptor with env-
expression vectors should trigger syncytium formation. Accordingly, transfection of 
AH927-CD134 cells with  constructs bearing the env genes from primary isolates (Fig. 
3E-G) led to the development of syncytia whereas no syncytia were observed in the 
control cultures (Fig. 3A-C) expressing the FeLV-CR. In contrast, FIV-PET env 
(derived from a FIV strain analogous to CD4-independent strains of HIV (14)) 
induced syncytium formation in both the CD134 (Fig. 3H) and FeLV-CR-expressing 
(Fig. 3D) cells, consistent with this Env interacting with CXCR4 in the absence of a 
primary receptor (15).   
Human cells are refractory to infection with primary strains of FIV (16). We 
therefore examined species-specificity of the interaction between FIV and CD134. The 
human cell line HeLa was stably transduced with either feline or human CD134 and 
surface expression of CD134 was confirmed by flow cytometry (Fig. 4B). Although 
ectopic expression of feline CD134 rendered HeLa cells permissive for infection with 
primary FIV strain GL8 or TM2 pseudotypes (Fig. 4A) human CD134 expression had 
little effect. In contrast, the susceptibility of the feline and human CD134-expressing 
cells to HIV pseudotypes with VSV-G envelope was broadly similar to the control 
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HeLa cells.  Similarly,  feline, but not human, CD134 expression permitted infection 
with HIV pseudotypes bearing FIV envelopes and encoding GFP (Fig. 4B). These 
results suggest that the specificity of the  interaction between the virus and its primary 
receptor may be a major determinant of the species specificity of FIV.  
Since infection with both primary and cell culture adapted strains of FIV is 
CXCR4-dependent (8,9), we determined whether CD134-dependent infection required 
co-expression of CXCR4.  HeLa cells express high levels of CXCR4 and human 
CXCR4 is an efficient co-receptor for FIV (17). Infection of HeLa-CD134 cells with 
GL8 and TM2 pseudotypes was inhibited efficiently by the selective CXCR4 
antagonist AMD3100 while infection with control HIV (VSV) pseudotypes was not 
affected (Fig. 4C), confirming an absolute requirement for both receptor and co-
receptor.   
Further evidence for a role for CD134 in viral infection was provided by down-
regulation of CD134 from the surface of FIV infected cells (Fig. S2). Moreover, 
CD134-expressing cells expressed similar levels of CXCR4 to control cells, indicating 
that CD134 did not mediate its effect on FIV infection by modulating CXCR4 
expression (Fig. S3). 
We have shown that CD134 functions as a novel primary receptor for an 
immunodeficiency-causing lentivirus. CD134 expression is largely restricted to CD4+ 
T lymphocytes (12,18-20), however, in humans and mice CD134 is also expressed at 
lower levels on  activated CD8+ T cells (18,21), macrophages and activated B cells 
(22).   CD4+ T cells are the primary target for FIV in early infection, while in chronic 
infection CD8+ T cells and B cells are also infected  (23,24), the tropism of FIV in 
vivo is consistent with the predicted expression of CD134. In addition, the viral co-
receptor CXCR4 is expressed widely in the cat (activated T cells, B cells and 
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monocytes (25)) and since some primary and cell culture adapted strains of FIV can 
infect via CXCR4 alone (26) (CD134-independent infection), the broadening of cell 
tropism of the virus in chronic infection may represent a shift towards CD134-
independent infection. 
Signalling through CD134 plays a crucial role in the survival and proliferation 
of CD4+ T cells that have encountered antigen (20). By targeting CD134-expressing 
cells, FIV would selectively deplete a subset of CD4+ T cells that is integral to the 
development of antigen-specific T cell responses. In contrast, by utilising CD4 as a 
primary receptor, HIV has the potential to infect all CD4+ T cells and induce a more 
profound immune defect. However, the cell tropism of HIV is restricted by the 
expression of the viral co-receptor which, for the majority of strains that are 
transmitted, is CCR5. CCR5 expression on CD4+ T cells is restricted to an effector / 
memory T cell subset (27,28). Thus despite the use of distinct primary binding 
receptors, both the human and feline viruses selectively impair antigen-specific helper 
T cell responses.  
Vaccination may lead to enhancement of infection in the feline model of AIDS  
(29). Our new data may shed new light on the mechanism of enhancement, since 
CD134 is a T cell activation antigen with expression in vivo restricted predominately 
to CD4+ T cells.  Vaccination may induce an expansion of a population of cells 
expressing the viral receptor so that if sterilising immunity is not achieved, vaccination 
may prove counter-productive.  
That two lentiviruses with host species as divergent as human beings and the 
domestic cat should use distinct primary receptors to target the similar T cell subsets 
underlines the central role of CD4+ T lymphocyte infection in the pathogenesis of 
AIDS. Whether the feline and human lentiviruses evolved from a common ancestor, 
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such as a CD4 or CD134-independent virus, is an intriguing question for the 
development of viral virulence, and this study represents the first step towards 
providing a solution.  
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Figure legends 
 
Fig. 1. Molecular cloning and characterisation of feline CD134. (A) Alignment of 
feline and human CD134. Homologous amino acids are shaded light, identical 
residues are shaded dark. TM, transmembrane region. (B) Binding of FIV to CD134 
expressing cells. Cell cultures transduced with CD134 or CD2 were incubated with 
culture supernatant from FIV-infected (thick line) or uninfected (thin line) cells 
followed by FIV Env detection by flow cytometry. 
  
Fig. 2.  CD134 expression renders feline cells permissive to infection with FIV. (A) 
Flow cytometric analysis of CD134 expression on MCC cells. Control (solid 
histogram) or anti-CD134 (Ber-ACT35, open histogram). Percentage positive is 
shown. (B) Immunoblot analysis with rabbit anti-rat OX40.  MCC cells transduced 
with vector only (CON) were compared with cells transduced with the CD134 
expression vector. A ~45kDa species was detected in CD134-transduced cells 
(arrowed). (C) fCD134 expression renders MCC cells permissive of productive 
infection with primary strains of FIV.  MCC-CON or MCC-CD134 were infected with 
the GL8, F0425, F0827, F0795 and F0556 primary isolates of FIV. Reverse 
transcriptase activity in the culture supernatants was measured at 1, 4 and 6 days post-
infection. (D) Luciferase activity in MCC-CON or MCC-CD134 infected with HIV 
(FIV) luciferase pseudotypes bearing the GL8 or TM2 Envs (mean +/-SE, n=4).   
 
Fig. 3.  CD134 expression renders AH927 cells permissive for syncytia formation 
mediated by FIV Env. FeLV-CR-expressing cells (A-D) or CD134-expressing cells 
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(E-H) were transfected with pVR1012 expressing the GL8 (A, E),  F0425 (B, F), 
F0827 (C, G)  or PET (D, H) env genes.  
 
Fig. 4. CD134-mediated infection is species specific and CXCR4-dependent. (A) 
HeLa cells transduced with retroviral vectors bearing  feline or human CD134 cDNAs, 
or a vector only control were infected with HIV (FIV) (GL8 or TM2) or HIV (VSV) 
luciferase pseudotypes (mean +/-SE, n=4). (B)  CD134-dependent infection of HeLa 
cells expressing feline CD134 by HIV (FIV) pseudotypes bearing a GFP marker gene. 
CD134 and GFP expression were  analyzed by flow cytometry.  (C) HeLa cells 
expressing feline CD134 were infected with HIV (FIV) (GL8  or TM2) or HIV (VSV)  
luciferase pseudotypes in the presence of 0, 10, 100 or 1000 ng/ml CXCR4-antagonist 
AMD3100 (mean +/-SE, n=4). 
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